Arnon Nagler, MD, from Sheba Medical Center, Tel Hashomer, Israel, discusses why immunotherapy is his highlight from the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain. Prof Nagler explains the importance of chemotherapy in clinical practice at the moment but also, that it is a very crude treatment. Then he discusses the new developments in immunotherapy, such as monoclonal antibodies and chimeric antigen receptors (CARs) and their promise for the future of cancer therapy.
Author: Editor
Ali Bazarbachi, MD, from the American University of Beirut, Beirut, Lebanon explains his research into the use of FLT3 inhibitors in acute myeloid leukemia (AML). FLT3 inhibitors are tyrosine kinase inhibitors and in the first-line treatment of AML combined with chemotherapy, they have shown a survival advantage. Further, they can be used in relapsed AML in transplanted and non-transplanted patients. The most promosing setting for FLT3 inhibitors is in maintenance therapy after allogeneic stem cell transplantation to avoid relapse. Prof Bazarbachi further discusses the implications of these results and the ongoing clinical trials in this area. According to Prof Bazarbachi,…
Arnon Nagler, MD, from Sheba Medical Center, Tel Hashomer, Israel, discusses the use of drugs and transplantation in acute leukemias. Prof Nagler describes how drug therapy and transplantation are used together in order to achieve the best outcomes for the patients. For example, with the help of the drugs, the mass of a tumor can be reduced pre-transplant, which in turn means, that less chemotherapy may be required. Recorded at the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain.
Ann Leen, PhD, from Baylor College of Medicine, Houston, TX, US, provides an overview of the safety and effectivness of virus-specific T cells and their use in transplant patients. According to Dr Leen, there is a lot of research focusing around the use of algorithms to help phyisicans choose the right product for their patients and the next step would be a registration trial. She further describes how referrals usually come from transplant physicians. In order to provide the virus-specific T cells to the patients, they require the HLA characteristics of the patient and the details of their infection. Recorded…
Ali Bazarbachi, MD, from the American University of Beirut, Beirut, Lebanon provides an overview of FLT3 mutations in acute myeloid leukemia (AML) at the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain. FLT3 is a tyrosine kinase and FLT3 mutations are seen in over 30% of AML patients according to Prof Bazarbachi. FLT3 mutations are associated with a poor prognosis and currently, researchers are investigating the use of tyrosine kinase inhibitors to target FLT3 mutations.
Ivan Borello, MD from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Batlimore, MD discusses the highlights in immunotherapy and in particular CAR T-cells for multiple myeloma (MM) from the Myeloma 2016 meeting held in Boston, MA with Edward Stadtmauer, MD from the University of Pennsylvania, Philadelphia, PA, James Kochenderfer, MD from the National Cancer Institute, Bethesda, MD and Michael Hudecek, MD from the University of Würzburg, Würzburg, Germany. Prof Stadtmauer discusses his talk on the CD19 targeted T-cells and the rationale behind targeting tumors that are not expressing CD19. They further talk about the B-cell maturation antigen (BCMA) and…
Stephen Russell, MD, PhD from the Mayo Clinic, Rochester, MN discusses highlights from the session ‘Environment biology insights’ in multiple myeloma (MM) held at the Myeloma 2016 meeting in Boston, MA with Dirk Hose, MD from the University of Heidelberg, Heidelberg, Germany and Suzanne Lentzsch, MD, PhD from the Columbia University Medical Center, New York, NY. Prof Russell first highlights the talk by Madhav Dhodapkar from the Yale Cancer Center on monoclonal gammopathy of undetermined significance (MGUS). Dr Hose then discusses his talk on the evolution of MGUS to multiple myeloma (MM). According to Dr Hose, the main factors driving…
Philippe Moreau, MD from the University Hospital of Nantes, Nantes, France gives an overview of the Cassiopeia trial on daratumumab in transplant eligible multiple myeloma (MM) patients. The trial compares bortezomib, thalidomide, dexamethasone (VTD) followed by stem cell transplantation, followed by two cycles of consolidation therapy with VTD with or without daratumumab (NCT02541383). The primary endpoint is stringent complete remission (CR). Within the same study, there is a second randomization with daratumumab maintenance for two years versus no maintenance. The goal is to show that the addition of daratumumab will improve the quality of response and therefore progession-free survival and…
Paul Richardson, MD from the Dana-Farber Cancer Institute, Boston, MA discusses his talk on ‘Perspectives on future paths to cure’ in multiple myeloma (MM) held at the Myeloma 2016 meeting in Boston, MA. Dr Richardson discusses monoclonal antibodies, proteasome inhibitors, immunomodulatory drugs (IMiDs), HDAC inibitors as well as the role of transplants. He first discusses daratumumab, which is considered a breakthrough drug in MM. While daratumumab is used in monotherapy, elotuzumab needs to be combined with proteasome inhibitors or IMiDs. Further isatuximab, which targets CD38, appears to very promising. In terms of the new proteasome inhibitors, Dr Richardson discusses ixazomib,…
Ola Landgren, MD, PhD from the Memorial Sloan Kettering Cancer Center, New York, NY gives an overview of his talk on the applications of minimal residual disease (MRD) testing in multiple myeloma (MM) held at the Myeloma 2016 meeting in Boston, MA. Dr Landgren outlines how two years ago, around 30% of institutions conducted flow based MRD testing while now, it is 60%. He further discusses the work that remains to be done in this field. According to Dr Landgren, MRD has arrived in MM due to the various new therapies that are now available. In terms of applications for…
Nikhil Munshi, MD from the Dana-Farber Cancer Institute, Boston, MA gives an overview of the data presented on the Dana-Farber Cancer Institute (DFCI) genomics program in multiple myeloma (MM) at the Myeloma 2016 meeting held in Boston, MA. The summary of the DNA data shows many mutations whereby no single mutation is more frequent that 20%. The data provides information on potential new targets, such as in the RAS, RAF and p53 pathway. Further, there are multiple clones in myeloma, which change over time which means that genomic analysis at diagnosis may not be adequate. Moreover, Dr Munshi discusses the…
At the Myeloma 2016 meeting held in Boston, MA, Daniel Auclair, PhD, from the Multiple Myeloma Research foundation (MMRF) discusses highlights from the meeting for patients with Kenneth Anderson, MD from the Dana-Farber Cancer Institute, Boston, MA, Keith Stewart, MB, ChB from the Mayo Clinic, Scottsdale, AZ and Sagar Lonial, MD from the Winship Cancer Institute, Atlanta, GA. Prof Anderson highlights immune therapies and in particular, check-point inhibitors, CAR T-cell therapy and immunomodulatory drugs (IMiDs) such as pomalidomide and lenalidomide. According to Prof Anderson, the main message is that there are many immune therapies now and drug combinations will play…
Lawrence Boise, PhD, from the Winship Cancer Institute, Atlanta, GA, discusses the mechanism of action of venetoclax and next steps for the drug in multiple myeloma (MM). Venetoclax is an inhibitor of BCL-2 and has recently been approved for the treatment of chronic lymphocytic leukemia (CLL). According to Prof Boise, only a small fraction of multiple myeloma patients appear to be sensitive to venetoclax and the next step is to find a marker that can identify those patients. Another area of research concerns drug combinations, i.e. finding drugs such as dexamethasone, that can be combined with venetoclax. Recorded at the…
Jesús San Miguel, MD, PhD, from the University of Navarra, Navarra, Spain gives an overview of his talk on ‘Immunotherapy checkpoint inhibitor trials’ presented at the Myeloma 2016 meeting in Boston, MA. First, Prof San Miguel discusses the lenalidomide and pembrolizumab KEYNOTE-023 trial (NCT02036502). The treatment was well tolerated and the response rate was 76% for the overall population and 50% for the double refractory population. Then, he discusses the trial of pembrolizumab plus pomalidomide (NCT02289222); the response rate was 60% for the overall population and 50% for the double refractory population. Recorded at the Myeloma 2016 meeting held in…
Michel Delforge, MD, PhD from the University Hospital Leuven, Leuven, Belgium gives an overview of the mechanism of action of proteasome inhibitors. Prof Delforge gives a detailed outline of how the proteasome is targeted. He further discusses the different classes of proteasome inhibitors, i.e. the boronic acid derivatives (bortezomib, ixazomib), epoxyketone derivatives (carfilzomib, oprozomib)and salinosporamide derivatives (marizomib). Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
Carlos Fernandez de Larrea, MD, PhD from the Hospital ClÃnic de Barcelona, Barcelona, Spain discusses the definition of complete remission (CR) in multiple myeloma (MM). The current definiton of CR requires a negative serum and IFE and less than 5% bone marrow plasma cells (BMPCs). However, two-thirds of patients with CR still relapse and the aim is to be able to identify those patients who are really cured. Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
MarÃa-Victoria Mateos, MD, PhD, from the University Hospital of Salamanca, Salamanca, Spain gives an overview of the challenges associated with assessing and treating smouldering myeloma. Smouldering myeloma is a heterogeneous disease and Dr Mateos explains how the difficulty in assessing whether a patient is at risk of progressing to symptomatic myeloma, can vary from case to case. She explains the use of the Mayo Clinic model and monitoring strategies in case of low, intermediate and high risk of progression to myeloma. For high risk patients, Dr Mateos suggests that in future, they will be offered an early treatment. Recorded at…
Michel Delforge, MD, PhD from the University Hospital Leuven, Leuven, Belgium gives an overview of the two trials on second generation proteasome inhibitors. First, Prof Delforge discusses the ENDEAVOUR trial (NCT01568866), which compared carfilzomib plus dexamethasone (Kd) with bortezomib plus dexamethasone (Vd). Progression-free survival doubled in the Kd arm compared to the Vd arm and further, the depth of response was superior in the Kd arm. Prof Delforge also discusses the occurence of side effects such as peripheral neuropathy and cardiovascular toxicity. Prof Delforge further discusses the ASPIRE trial (NCT01080391) comparing carfilzomib, lenalidomide and dexamethasone (CRd) vs lenalidomide and dexamethasone…
Thierry Facon, MD, PhD, from Hospital Claude Huriez, Lille, France provides an overview of the topics and sessions covered at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) held in Paris, France. Some of the areas covered at the meetings were the biology and genetics of the disease as welll as imaging techniques and minimal residual disease assessment. Prof Facon further discusses the approval of new drugs for multiple myeloma (MM), which include pomalidomide, panastinomab, ixazomib, elotuzumab and daratumumab. According to Prof Facon, it may be possible to cure patients with MM in future. He further discusses PD-1…
Michel Delforge, MD, PhD from the University Hospital Leuven, Leuven, Belgium discusses the role of bortezomib in relapsed/refractroy multiple myeloma (MM). Prof Delforge, discusses the various trials that showed the superiorty of the proteasome inhibitor bortezomib in terms of response and time to progression. According to Prof Delforge, bortezomib is an ideal backbone and is combined with dexamethasone alone, or dexamethasone and a third agent, for example chemotherapy or immunomodulatory drugs (IMiDs) such as thalidomide, lenalidomide, pomalidomide. Bortezomib can further be combined with histone deacetylase (HDAC) inhibitors like vorinostat and panobinostat. Prof Delforge discusses trials results for the various combinations.…
Sagar Lonial, MD, from Emory University Winship Cancer Institute, Atlanta, GA, USA provides an overview of monoclonal antibodies and checkpoint inhbitors for multiple myeloma at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) held in Paris, France. Currently, two antibodies are approved for routine use in the USA: elotuzumab, which targets SLAMF7 and is combined with lenalidomide and dexamethasone, and daratumumab, which is currently approved as a single agent. Checkpoint inhibitors are another important class of drugs according to Prof Lonial. Several trials have been launched looking into nivolumab and pembrolizumab, which target PD-1, in combination with lenalidomide…
Paula RodrÃguez, MD, PhD from the University Clinic of Navarra, Pamplona, Spain gives an overview of her talk on anticancer immunity in multiple myeloma (MM) held at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. Cancer cells have varied mechanisms to evade immune control and the basis of anticancer immunity is to disrupt these mechanisms. According to Dr RodrÃguez, there are four approaches to disrupt these mechanisms: monoclonal antibodies, boosting the effector cells with adoptive therapy such as CAR T-cells, vaccination or using drugs like checkpoint inhibitors to overcome the immune suppression. Dr RodrÃguez further…
Hervé Avet-Loiseau, MD, PhD from the Cancer Research Center of Toulouse, Toulouse, France talks about the progress that has been made in treatment of multiple myeloma (MM). According to Prof Avet-Loiseau, in five years from now, it may be possible to cure around 50% of patients with MM with intensive therapy. Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
Jean-Luc Harousseau, MD, from the University of Nantes, Nantes, France gives an overview of his talk on the access to novel drugs in multiple myeloma (MM) held at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. Prof Harousseau argues that it is important to take into consideration, that several new drugs have been approved in recent years and life expectancy for patients has improved. He further discusses the issue of drug prices and the sustainability of healthcare systems as well as the strategies employed by various countries, such as Germany and France, to assess the…
Hervé Avet-Loiseau, MD, PhD from the Cancer Research Center of Toulouse, Toulouse, France discusses the impact of next-generation sequencing (NGS) on the treamtment of multiple myeloma (MM). First, NGS may be used to assess the prognosis for patients in future. It may also be used to identify molecular targets for individual patients and help physicians choose the right drug for their patient. According to Prof Avet-Loiseau, it may also be used for the assessment of minimal residual disease (MRD). Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
Evangelos Terpos, MD, PhD, University of Athens, Athens, Greece discusses the open issues in the use of imaging techniques for the assessment of response in multiple myeloma (MM). One question concerns the MRI and how to better define complete response and further how often the MRI needs to be repeated. The same questions apply to PET-CT. Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
Jean-Luc Harousseau, MD, from the University of Nantes, Nantes, France discusses the role of the patient in the debate around the access to and affordability of novel drugs in multiple myeloma (MM). Prof Harousseau argues that patients should be aware of novel drugs and their benefit, which may not always be significant. He further argues that like doctors, patients should take into consideration the cost-effectiveness ratio and further, that patients should be involved in the evaluation of novel drugs. Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
Evangelos Terpos, MD, PhD, from the University of Athens, Athens, Greece discusses the limitations and challenges associated with using various imaging techniques to assess disease response in multiple myeloma (MM). According to Dr Terpos, with MRI it is possible to decide which patients to treat at diagnosis based on focal lesions while the PET-CT has the advantage of being able to better depict the living cells. Dr Terpos further discusses the benefits of diffusion weighted imaging MRI. Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
Antonio Palumbo, MD, from the University of Turin, Turin, Italy provides an overview of the diagnostic criteria for smouldering myeloma. According to Dr Palumbo, hematological test plus a M-protein evaluation are the starting point and if indicated, this is followed by a bone marrow biospy and low-dose CT scan. Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
Carlos Fernandez de Larrea, MD, PhD from the Hospital ClÃnic de Barcelona, Barcelona, Spain discusses which techniques can be used to establish disease response in multiple myeloma (MM). For the detection of minimal residual disease (MRD), the most established technique is flow cytometry. In terms of imagng, clear criteria for the evaulation of PET/CT are required. Dr de Larrea further discussses the importance of standardizing the various techniques. Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
Antonio Palumbo, MD, from the University of Turin, Turin, Italy provides treatment advice for smouldering myeloma. The key message, according to Dr Palumbo, is that today, smouldering myeloma is defined by the presence of 3g/dL of M-component and at least 10% bone marrow plasma cells. Further, Dr Palumbo discusses ultra high-risk smouldering myeloma and high-risk smouldering myeloma. Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
Antonio Palumbo, MD, from the University of Turin, Turin, Italy provides advice on how to treat multiple myeloma (MM). For patients younger than 75, autologous transplantation remains the standard of care and Dr Palumbo also suggests a three-drug combination induction therapy. For patients who are not eligible for a transplant, the advice is also a three-drug combination, which includes proteasome inhibitors plus an alkylating agent or a proteasome inhibitor plus IMiDs. For frail patients who are not transplant eligible and also have co-morbidities, Dr Palumbo suggests a two-drug combination therapy. Recorded at the 2016 World Congress on Controversies in Multiple…
In this introductory video on head and neck cancer, radiation oncologist Dr. Carryn Anderson of the University of Iowa defines head and neck cancers. Listen as Dr. Anderson explains typical symptoms and common causes. She also describes treatment standards and lists the customary members of your healthcare team. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital, Paris, France and Arnon Nagler, MD, from the Sheba Medical Center, Tel Hashomer, Israel, discuss the highlights from the second day of the 2016 World Congress on Controversies in Multiple Myeloma (COMy) held in Paris, France. First, Prof Nagler highlights the presentations that focused on the current situation in Asia and how therapies for multiple myeloma (MM) all around the world are improving. Prof Mohty also discusses the trials that are being run in China. Prof Nagler and Prof Mohty then discuss the Patient Advocate Meeting and the importance of the patient voice…
Jesús San Miguel, MD, PhD, from the University of Navarra, Navarra, Spain gives an overview of immunomodulatory drugs (IMiDs) thalidomide, lenalidomide and pomalidomide for multiple myeloma (MM). According to Prof San Miguel, these drugs have reinforced the value of the immune system. The tumor cells use various mechanisms to evade immune system control, such as the PD-1/PDL-1 pathway. The monoclonal antibody pembrolizumab can release this particular break on the immune system. Prof San Miguel explains how preliminary data shows, that at the time of minimal residual disease (MRD) and relapse, the PD-1 is expressed on the T-cells and PDL-1 on…
Philippe Moreau, MD from the University Hospital of Nantes, Nantes, France gives an overview of a prospective comparison on PET-CT and MRI in multiple myeloma (MM). The primary endpoint of the trial (NCT01309334) was to compare MRI and PET-CT in regard to the number of bone lesions at diagnosis and the secondary endpoint was to look at the prognostic impact of both imaging techniques. According to Prof Moreau, both techniques are equally effective at identifying the number bone lesions and PET-CT was able to predict progression-free survival (PFS). Prof Moreau argues that PET-CT is a very important imaging technique. Recorded…
Jean-Luc Harousseau, MD, from the University of Nantes, Nantes, France gives two message to stakeholders, such as pharmaceutical companies, the payers, such as healthcare providers, and doctors concerning the access to and affordability of novel drugs in multiple myeloma (MM). According to Prof Harousseau, the stakeholders should find a fair price for the drugs and act transparently. The payers should focus on the patient pathway and healthcare organization. Further, doctors should not only consider the efficacy but also the efficiency. His second message to the stakeholders, payers and doctors is to work together rather than against each other. Recorded at…
Paula RodrÃguez, MD, PhD from the University Clinic of Navarra, Pamplona, Spain gives an overview of the two main PD-1 checkpoint inhibitors, nivolumab and pembrolizumab. A Phase I trial of nivolumab as a single agent for a group of hematological malignancies, showed an overall response rate of around 40% for diffuse large B-cell and follicular lymphoma (NCT02038933 and NCT02038946) and an overall response rate of 87% in Hodgkin lymphoma (NCT01592370). In multiple myeloma (MM), nivolumab as a single agent only achieved a stabilization of the disease and according to Dr RodrÃguez, these drugs need to be combined in MM. Dr…
Michel Delforge, MD, PhD from the University Hospital Leuven, Leuven, Belgium provides an overview of the approval of proteasome inhibitors in relapsed/refractory multiple myeloma (MM) since 2003. Prof Delforge first discusses bortezomib, which was first approved by the US Food and Drug Administration (FDA) in 2003 and later, was approved for the use as upfront therapy in Europe and the US. Based on the success story of bortezomib, second generation proteasome inhibitors such as carfilzomib in combination with lenalidomide and dexamethasone, have been approved. Ixazomib, an oral proteasome inhibitor, has also been approved. Recorded at the 2016 World Congress on…
Hervé Avet-Loiseau, MD, PhD from the Cancer Research Center of Toulouse, Toulouse, France discusses his talk on prognostic factors in multiple myeloma (MM) held at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. According to Prof Avet-Loiseau, it is important to categorize the prognostic factors. Some prognostic factors, such as age and co-morbidities, are related to the patient. He further discusses prognostic factors related to the tumor clone, such as cytogenetics, and prognostic factors that are only identified after treatment, i.e. response to treatment. Prof Avet-Loiseau argues that in light of minimal residual disease (MRD)…
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Alessandro M. Vannucchi discusses the use of novel agents and combination therapies in the treatment of myelofibrosis (MF). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Nicolaus Kröger discusses the influence of mutational status on the timing, outcome and post-transplant management of patients with myelofibrosis (MF). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Mary F. McMulllin discusses how to manage side effects of JAK inhibitors in the treatment of myelofibrosis (MF). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Srdan Verstovsek provides an update on several JAK inhibitors in development for use in the treatment of myelofibrosis (MF). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.
In this presentation from the 2016 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, held August 26-27 in Alexandria, VA, Dr. Eilliot Winton examines whether there is any real clinical utility in utilizing mutation-based risk stratification approaches in the treatment of patients with myelofibrosis. Earn accreditation for a related activity at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7221 © 2016 Imedex, LLC.
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Theo De Witte discusses novel strategies to prevent relapse of myelodysplastic syndromes (MDS) after allogeneic transplantation has been performed. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Michael Pfeilstöcker discusses newer therapeutic agents for use in the treatment of myelodysplastic syndromes (MDS) when hypomethylating agents (HMAs) fail. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Martin Jädersten provides an update on the use of erythropoiesis-stimulating agents and other growth factors in the treatment of low-risk myelodysplastic syndromes (MDS). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Fabio Efficace discusses quality of life as a treatment goal in myelodysplastic syndromes (MDS). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Torsten Haferlach discusses whether mutational profiling in patients with myelodysplastic syndromes (MDS) is ready for everyday use in the clinic. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.